Prexton Therapeutics is the first spin-off company from EPP Fund. The company is developing programs in Parkinson’s disease focused on targeting the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton Therapeutics is based in Geneva, Switzerland.
Total raised: $41.07M
Investors 3
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | Seroba Lif... | seroba-lif... |
| - | Forbion | forbion.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.02.2017 | Series B | $31.07M | Forbion |
| 24.02.2015 | Series A | $10M | - |
Mentions in press and media 16
| Date | Title | Description |
| 01.02.2019 | Swisscom and Prexton awarded at Global Corporate Venturing Summit | |
| 19.03.2018 | Term Sheet — Monday, March 19 | ANTITRUST SHOWDOWN Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop Here’s why this matters: • The merger fight has broad implications for various industries, specifically media and tech. ... |
| 16.03.2018 | Lundbeck to acquire Prexton for up to EUR 900 million | |
| 16.03.2018 | Lundbeck to Acquire Prexton Therapeutics, for €905M | H. Lundbeck A/S, a (OMX: LUN) Danish international pharmaceutical company, is to acquire Oss, the Netherlands- and Geneva, Switzerland-based biopharmaceutical company Prexton Therapeutics BV, for €905m. Under terms of the agreement, Lundbec... |
| 16.03.2018 | Ysios realiza la 1ª desinversión de su 2º fondo tras la venta de Prexton Therapeutics a Lundbeck por €905M | 16/03/2018 Nota de prensa YSIOS REALIZA LA PRIMERA DESINVERSIÓN CON SU SEGUNDO FONDO TRAS LA VENTA DE PREXTON THERAPEUTICS A LUNDBECK POR €905 MILLONES. La gestora de capital riesgo (venture capital) Ysios Capital, ha anunciado hoy la pr... |
| 04.08.2017 | Prexton announces launch of phase II clinical testing in Parkinson’s disease | |
| 07.02.2017 | Prexton Therapeutics raises CHF31 million | |
| 07.02.2017 | Prexton Therapeutics €29M in Series B Financing | Prexton Therapeutics, a Geneva, Switzerland and Amsterdam, The Netherlands-based biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, closed a €29 million ($31M) Seri... |
| 07.02.2017 | Prexton Therapeutics, participada por Ysios, cierra una ronda de €29 millones | 07/02/2017 Nota de prensa PREXTON THERAPEUTICS, PARTICIPADA POR YSIOS CAPITAL, CIERRA UNA RONDA DE €29 MILLONES. Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson´s therapeutic – Prex... |
| 07.02.2017 | Term Sheet — Tuesday, February 7 | SURVEY SAYS Earlier this year I asked Term Sheet readers to take a confidence survey created by professional services provider Semaphore. More than 500 of you did (around 30% from the private equity, 26% from venture capital, with the rest ... |
Show more